Stalicla

Switzerland
Hasle, Lucerne, Switzerland, 1202

Company profile

Stalicla company profile

Stalicla is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders. Stalicla’s unique approach addresses a principal weakness in the drug development process for NDD’s and neuropsychiatric disorders: behavior is a terrible biomarker. Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This has contributed to drug development failure by diluting true responders in a population of patients with heterogeneous biology.

Business identity

Contact email
[email protected]
Phone number
+41 22-545-12-42
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2017-05-01, Month

Headquarters

Postal code
1202
Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
9
Total equity funding
$38M
Last funding
Corporate Round / $2.5M / 2025-06-30
Last equity funding
Corporate Round / $2.5M
Investors
4
Lead investors
3
Founders
1
Articles
47

Founders and investors

Founders

Lynn Durham

Lead investors

AA SonsAddex TherapeuticsSPRIM Global Investments

Investors

AA SonsAddex TherapeuticsLIFTTSPRIM Global Investments